^
Association details:
| Biomarker: | RB1 mutation |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Abstract 2047: Association of retinoblastoma function with response to immuno-oncology treatment in patients with small cell lung cancer
Published date:
05/15/2020
Excerpt:
Overall survival (OS) with NIVO was lower in RB1MUT patients compared with RB1WT (HR = 1.46 [1.02–2.1]). RB1 mutation status was not associated with OS in patients receiving NIVO+IPI. Similar trends were observed for objective response rates.
DOI:
10.1158/1538-7445.AM2020-2047
Trial ID:
